Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. The company is headquartered in Wilmington, Delaware and currently employs 2,617 full-time employees. The firm operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The firm's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
Follow-Up Questions
Quel est le ratio P/E de Incyte Corp (INCY) ?
Le ratio P/E de Incyte Corp est de 508.682
Qui est le CEO de Incyte Corp ?
Mr. Bill Meury est le President de Incyte Corp, il a rejoint l'entreprise depuis 2025.
Quelle est la performance du prix de l'action INCY ?
Le prix actuel de INCY est de $104.01, il a increased de 2.4% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Incyte Corp ?
Incyte Corp appartient à l'industrie Biotechnology et le secteur est Health Care
Quel est la capitalisation boursière de Incyte Corp ?
La capitalisation boursière actuelle de Incyte Corp est de $20.3B
Est-ce que Incyte Corp est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 24 analystes ont établi des notations d'analystes pour Incyte Corp, y compris 10 achat fort, 8 achat, 15 maintien, 1 vente et 10 vente forte
